5iwl › Citations

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J
J Clin Invest 126 2610-20 (2016)
Cited: 242 times
EuropePMC logo PMID: 27294525

Abstract

Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited treatment options. CD47 is a cell-surface molecule that promotes immune evasion by engaging signal-regulatory protein alpha (SIRPα), which serves as an inhibitory receptor on macrophages. Here, we found that CD47 is highly expressed on the surface of human SCLC cells; therefore, we investigated CD47-blocking immunotherapies as a potential approach for SCLC treatment. Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture. In a murine model, administration of CD47-blocking antibodies or targeted inactivation of the Cd47 gene markedly inhibited SCLC tumor growth. Furthermore, using comprehensive antibody arrays, we identified several possible therapeutic targets on the surface of SCLC cells. Antibodies to these targets, including CD56/neural cell adhesion molecule (NCAM), promoted phagocytosis in human SCLC cell lines that was enhanced when combined with CD47-blocking therapies. In light of recent clinical trials for CD47-blocking therapies in cancer treatment, these findings identify disruption of the CD47/SIRPα axis as a potential immunotherapeutic strategy for SCLC. This approach could enable personalized immunotherapeutic regimens in patients with SCLC and other cancers.

Reviews - 5iwl mentioned but not cited (3)

  1. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function. Jalil AR, Andrechak JC, Discher DE. Antib Ther 3 80-94 (2020)
  2. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Huang B, Bai Z, Ye X, Zhou C, Xie X, Zhong Y, Lin K, Ma L. Comput Struct Biotechnol J 19 5494-5503 (2021)
  3. New hope for tumor immunotherapy: the macrophage-related "do not eat me" signaling pathway. Deng H, Wang G, Zhao S, Tao Y, Zhang Z, Yang J, Lei Y. Front Pharmacol 14 1228962 (2023)

Articles - 5iwl mentioned but not cited (5)



Reviews citing this publication (112)

  1. Targeting macrophages: therapeutic approaches in cancer. Cassetta L, Pollard JW. Nat Rev Drug Discov 17 887-904 (2018)
  2. Tumor-associated macrophages: an accomplice in solid tumor progression. Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. J Biomed Sci 26 78 (2019)
  3. Small-cell lung cancer. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Nat Rev Dis Primers 7 3 (2021)
  4. Macrophages as tools and targets in cancer therapy. Mantovani A, Allavena P, Marchesi F, Garlanda C. Nat Rev Drug Discov 21 799-820 (2022)
  5. Phagocytosis checkpoints as new targets for cancer immunotherapy. Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Fu YX, Weissman IL. Nat Rev Cancer 19 568-586 (2019)
  6. Small-cell lung cancer: what we know, what we need to know and the path forward. Gazdar AF, Bunn PA, Minna JD. Nat Rev Cancer 17 725-737 (2017)
  7. Next generation of immune checkpoint inhibitors and beyond. Marin-Acevedo JA, Kimbrough EO, Lou Y. J Hematol Oncol 14 45 (2021)
  8. Unravelling the biology of SCLC: implications for therapy. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Nat Rev Clin Oncol 14 549-561 (2017)
  9. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H, Zhao H, Xu J, Evans CE, Jin H. Front Immunol 11 18 (2020)
  10. Cancer immunotherapy targeting the CD47/SIRPα axis. Weiskopf K. Eur J Cancer 76 100-109 (2017)
  11. Role of immune cells in the removal of deleterious senescent cells. Kale A, Sharma A, Stolzing A, Desprez PY, Campisi J. Immun Ageing 17 16 (2020)
  12. Macrophages in immunoregulation and therapeutics. Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Signal Transduct Target Ther 8 207 (2023)
  13. Cell Removal: Efferocytosis. Henson PM. Annu Rev Cell Dev Biol 33 127-144 (2017)
  14. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G, Janji B. Cells 8 E1083 (2019)
  15. What's New in SCLC? A Review. Oronsky B, Reid TR, Oronsky A, Carter CA. Neoplasia 19 842-847 (2017)
  16. Tumor-Associated Macrophage Status in Cancer Treatment. Malfitano AM, Pisanti S, Napolitano F, Di Somma S, Martinelli R, Portella G. Cancers (Basel) 12 E1987 (2020)
  17. Mechanisms of small cell lung cancer metastasis. Ko J, Winslow MM, Sage J. EMBO Mol Med 13 e13122 (2021)
  18. New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG. J Thorac Oncol 15 520-540 (2020)
  19. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, Zhai J, Mai S, Jiang J, Wang Z, Wu H, Cai K. J Immunol Res 2019 1919082 (2019)
  20. Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Front Immunol 12 642285 (2021)
  21. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. Murata Y, Saito Y, Kotani T, Matozaki T. Cancer Sci 109 2349-2357 (2018)
  22. Advancing to the era of cancer immunotherapy. Wang Y, Wang M, Wu HX, Xu RH. Cancer Commun (Lond) 41 803-829 (2021)
  23. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Qiu Y, Chen T, Hu R, Zhu R, Li C, Ruan Y, Xie X, Li Y. Biomark Res 9 72 (2021)
  24. New Opportunities and Challenges to Defeat Cancer Stem Cells. Ramos EK, Hoffmann AD, Gerson SL, Liu H. Trends Cancer 3 780-796 (2017)
  25. MIF-Dependent Control of Tumor Immunity. Noe JT, Mitchell RA. Front Immunol 11 609948 (2020)
  26. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer. Cai J, Qi Q, Qian X, Han J, Zhu X, Zhang Q, Xia R. J Cancer Res Clin Oncol 145 1377-1385 (2019)
  27. The role of immunotherapy in small cell lung cancer. Calles A, Aguado G, Sandoval C, Álvarez R. Clin Transl Oncol 21 961-976 (2019)
  28. Immunotherapy in Small Cell Lung Cancer. Esposito G, Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Botti G, Totaro G, Muto P, Picone C, Normanno N, Morabito A. Cancers (Basel) 12 E2522 (2020)
  29. Hematoma clearance as a therapeutic target in intracerebral hemorrhage: From macro to micro. Wilkinson DA, Keep RF, Hua Y, Xi G. J Cereb Blood Flow Metab 38 741-745 (2018)
  30. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis. Yang H, Shao R, Huang H, Wang X, Rong Z, Lin Y. Cancer Med 8 4245-4253 (2019)
  31. Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, Schmidt LH. Cancers (Basel) 11 E690 (2019)
  32. Metabolic reprograming of tumor-associated macrophages. Puthenveetil A, Dubey S. Ann Transl Med 8 1030 (2020)
  33. Myeloid Cell Origins, Differentiation, and Clinical Implications. Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL. Microbiol Spectr 4 (2016)
  34. Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. Shue YT, Lim JS, Sage J. Transl Lung Cancer Res 7 21-31 (2018)
  35. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Zhou D, Luan J, Huang C, Li J. Gut Liver 15 500-516 (2021)
  36. Development of innate immune cells from human pluripotent stem cells. Bernareggi D, Pouyanfard S, Kaufman DS. Exp Hematol 71 13-23 (2019)
  37. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Tian Y, Zhai X, Han A, Zhu H, Yu J. J Hematol Oncol 12 67 (2019)
  38. Signal pathways and precision therapy of small-cell lung cancer. Yuan M, Zhao Y, Arkenau HT, Lao T, Chu L, Xu Q. Signal Transduct Target Ther 7 187 (2022)
  39. Putting the brakes on phagocytosis: "don't-eat-me" signaling in physiology and disease. Kelley SM, Ravichandran KS. EMBO Rep 22 e52564 (2021)
  40. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Tong B, Wang M. Future Oncol 14 2179-2188 (2018)
  41. CD81 as a tumor target. Vences-Catalán F, Duault C, Kuo CC, Rajapaksa R, Levy R, Levy S. Biochem Soc Trans 45 531-535 (2017)
  42. Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. Petty AJ, Owen DH, Yang Y, Huang X. Cancers (Basel) 13 5318 (2021)
  43. Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Leblond MM, Zdimerova H, Desponds E, Verdeil G. Cancers (Basel) 13 4712 (2021)
  44. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. Hargadon KM. Clin Transl Med 10 374-411 (2020)
  45. Killing SCLC: insights into how to target a shapeshifting tumor. Sutherland KD, Ireland AS, Oliver TG. Genes Dev 36 241-258 (2022)
  46. Nonresolving macrophage-mediated inflammation in malignancy. Murray PJ. FEBS J 285 641-653 (2018)
  47. The landscape overview of CD47-based immunotherapy for hematological malignancies. Yang H, Xun Y, You H. Biomark Res 11 15 (2023)
  48. Classification of Cell-in-Cell Structures: Different Phenomena with Similar Appearance. Borensztejn K, Tyrna P, Gaweł AM, Dziuba I, Wojcik C, Bialy LP, Mlynarczuk-Bialy I. Cells 10 2569 (2021)
  49. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Sung PS. Clin Mol Hepatol 28 333-350 (2022)
  50. Death begets a new beginning. Bosurgi L, Hughes LD, Rothlin CV, Ghosh S. Immunol Rev 280 8-25 (2017)
  51. Microglia and Other Myeloid Cells in Central Nervous System Health and Disease. Gopinath A, Collins A, Khoshbouei H, Streit WJ. J Pharmacol Exp Ther 375 154-160 (2020)
  52. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. Mukaida N, Nakamoto Y. World J Gastroenterol 24 1839-1858 (2018)
  53. Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance? Martori C, Sanchez-Moral L, Paul T, Pardo JC, Font A, Ruiz de Porras V, Sarrias MR. Cancers (Basel) 14 440 (2022)
  54. Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. Tian L, Lei A, Tan T, Zhu M, Zhang L, Mou H, Zhang J. Kidney Dis (Basel) 8 26-43 (2022)
  55. The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. Int J Mol Sci 21 E7820 (2020)
  56. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. Fang P, Zhou J, Liang Z, Yang Y, Luan S, Xiao X, Li X, Zhang H, Shang Q, Zeng X, Yuan Y. Front Immunol 13 975986 (2022)
  57. Molecular functions of SIRPα and its role in cancer. Takahashi S. Biomed Rep 9 3-7 (2018)
  58. SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs. Belluomini L, Calvetti L, Inno A, Pasello G, Roca E, Vattemi E, Veccia A, Menis J, Pilotto S. Front Oncol 12 840783 (2022)
  59. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Wang J, Ilyas S. Expert Opin Investig Drugs 30 429-438 (2021)
  60. Cancer Therapy Targeting CD47/SIRPα. Dizman N, Buchbinder EI. Cancers (Basel) 13 6229 (2021)
  61. Contribution of Macrophages and T Cells in Skeletal Metastasis. Mendoza-Reinoso V, McCauley LK, Fournier PGJ. Cancers (Basel) 12 E1014 (2020)
  62. Macrophages in multiple myeloma: key roles and therapeutic strategies. Opperman KS, Vandyke K, Psaltis PJ, Noll JE, Zannettino ACW. Cancer Metastasis Rev 40 273-284 (2021)
  63. Nanotherapeutic Shots through the Heart of Plaque. Kanthi Y, de la Zerda A, Smith BR. ACS Nano 14 1236-1242 (2020)
  64. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Deneka AY, Boumber Y, Beck T, Golemis EA. Cancers (Basel) 11 E1297 (2019)
  65. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy. Zanganeh S, Spitler R, Hutter G, Ho JQ, Pauliah M, Mahmoudi M. Immunotherapy 9 819-835 (2017)
  66. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. Behrens LM, van den Berg TK, van Egmond M. Cancers (Basel) 14 3366 (2022)
  67. Are there any theranostic biomarkers in small cell lung carcinoma? Pezzuto F, Fortarezza F, Lunardi F, Calabrese F. J Thorac Dis 11 S102-S112 (2019)
  68. The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. Chaintreuil P, Kerreneur E, Bourgoin M, Savy C, Favreau C, Robert G, Jacquel A, Auberger P. Front Immunol 14 1178337 (2023)
  69. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. Etxebeste-Mitxeltorena M, Del Rincón-Loza I, Martín-Antonio B. Front Immunol 12 717850 (2021)
  70. Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Akbay EA, Kim J. Transl Lung Cancer Res 7 464-486 (2018)
  71. Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. Reis-Sobreiro M, Teixeira da Mota A, Jardim C, Serre K. Cells 10 2364 (2021)
  72. Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer. Wong SK, Iams WT. Cancers (Basel) 13 506 (2021)
  73. Macrophages Interaction and MicroRNA Interplay in the Modulation of Cancer Development and Metastasis. Iurca I, Tirpe A, Zimta AA, Moldovan C, Gulei D, Slabý O, Condorelli G, Berindan-Neagoe I. Front Immunol 11 870 (2020)
  74. Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer. Lum C, Alamgeer M. Cancers (Basel) 11 E1570 (2019)
  75. Immunotherapy in small cell lung cancer: one step at a time: a narrative review. Dumoulin DW, Dingemans AC, Aerts JGJV, Remon J, De Ruysscher DKM, Hendriks LEL. Transl Lung Cancer Res 10 2970-2987 (2021)
  76. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy. Khan SU, Khan MU, Azhar Ud Din M, Khan IM, Khan MI, Bungau S, Hassan SSU. Front Immunol 14 1166487 (2023)
  77. Targeting CD47 as a Novel Immunotherapy for Breast Cancer. Chen C, Wang R, Chen X, Hou Y, Jiang J. Front Oncol 12 924740 (2022)
  78. Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy. Carpentier J, Pavlyk I, Mukherjee U, Hall PE, Szlosarek PW. Lung Cancer (Auckl) 13 53-66 (2022)
  79. Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Subbiah S, Nam A, Garg N, Behal A, Kulkarni P, Salgia R. J Clin Med 9 E2433 (2020)
  80. T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. Yang YL, Yang F, Huang ZQ, Li YY, Shi HY, Sun Q, Ma Y, Wang Y, Zhang Y, Yang S, Zhao GR, Xu FH. Front Immunol 14 1199173 (2023)
  81. The Immunoregulatory Role of the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes. Sharp RC, Brown ME, Shapiro MR, Posgai AL, Brusko TM. Front Immunol 12 739048 (2021)
  82. Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite. Gupta A, Taslim C, Tullius BP, Cripe TP. Cancer Drug Resist 3 550-562 (2020)
  83. Trogocytosis between Non-Immune Cells for Cell Clearance, and among Immune-Related Cells for Modulating Immune Responses and Autoimmunity. Li KJ, Wu CH, Lu CH, Shen CY, Kuo YM, Tsai CY, Hsieh SC, Yu CL. Int J Mol Sci 22 2236 (2021)
  84. Engineering cell signaling modulators from native protein-protein interactions. Zhang W, Ben-David M, Sidhu SS. Curr Opin Struct Biol 45 25-35 (2017)
  85. In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer. Reguart N, Marin E, Remon J, Reyes R, Teixido C. Drugs 80 241-262 (2020)
  86. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Chen Q, Guo X, Ma W. Oncol Res 32 49-60 (2023)
  87. Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective. Walia HK, Sharma P, Singh N, Sharma S. Curr Treat Options Oncol 23 268-294 (2022)
  88. Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Arnal-Estapé A, Foggetti G, Starrett JH, Nguyen DX, Politi K. Cold Spring Harb Perspect Med 11 a037820 (2021)
  89. Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Matthews AH, Pratz KW, Carroll MP. Cancers (Basel) 14 5906 (2022)
  90. cGAS-STING signaling pathway in intestinal homeostasis and diseases. Yang Y, Wang L, Peugnet-González I, Parada-Venegas D, Dijkstra G, Faber KN. Front Immunol 14 1239142 (2023)
  91. Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer. Kirk NA, Kim KB, Park KS. Exp Mol Med 54 2118-2127 (2022)
  92. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer. Otegui N, Houry M, Arozarena I, Serrano D, Redin E, Exposito F, Leon S, Valencia K, Montuenga L, Calvo A. Cancers (Basel) 15 3076 (2023)
  93. Combating challenges in CAR-T cells with engineering immunology. Wang CY, Ting Cheung SP, Sugimura R. Front Cell Dev Biol 10 969020 (2022)
  94. Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T. Guaitoli G, Neri G, Cabitza E, Natalizio S, Mastrodomenico L, Talerico S, Trudu L, Lauro C, Chiavelli C, Baschieri MC, Bruni A, Dominici M, Bertolini F. Int J Mol Sci 23 12728 (2022)
  95. Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective. Bleve A, Consonni FM, Porta C, Garlatti V, Sica A. Cancers (Basel) 14 510 (2022)
  96. Genetically-engineered mouse models of small cell lung cancer: the next generation. Oser MG, MacPherson D, Oliver TG, Sage J, Park KS. Oncogene 43 457-469 (2024)
  97. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies. Xu J, Shi Q, Wang B, Ji T, Guo W, Ren T, Tang X. Front Immunol 14 1257254 (2023)
  98. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Lau APY, Khavkine Binstock SS, Thu KL. Cancers (Basel) 15 5229 (2023)
  99. Deciphering the role of CD47 in cancer immunotherapy. Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P, Shi Y, Wang P, Fang L. J Adv Res 63 129-158 (2024)
  100. Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery. Xu Z, Lin X, Zeng H, Ma X, Nabi G, Abidin ZU, Wang L, Wang L. Front Genet 14 1238248 (2023)
  101. Targeting circulating tumor cells to prevent metastases. Gostomczyk K, Marsool MDM, Tayyab H, Pandey A, Borowczak J, Macome F, Chacon J, Dave T, Maniewski M, Szylberg Ł. Hum Cell 37 101-120 (2024)
  102. Tumor-associated macrophages as a potential therapeutic target in thyroid cancers. Zhu L, Li XJ, Gangadaran P, Jing X, Ahn BC. Cancer Immunol Immunother 72 3895-3917 (2023)
  103. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy. Karizak AZ, Salmasi Z, Gheibihayat SM, Asadi M, Ghasemi Y, Tajbakhsh A, Savardashtaki A. J Cancer Res Clin Oncol 149 511-529 (2023)
  104. [Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer]. Zhang S, Liu J, Cheng Y. Zhongguo Fei Ai Za Zhi 20 623-628 (2017)
  105. An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls. Salmaninejad A, Layeghi SM, Falakian Z, Golestani S, Kobravi S, Talebi S, Yousefi M. Clin Exp Med 24 156 (2024)
  106. Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity. Jiménez-Andrade Y, Flesher JL, Park JM. Hematol Oncol Clin North Am 38 1011-1025 (2024)
  107. Efferocytosis: a double-edged sword in microbial immunity. Mohammad-Rafiei F, Moadab F, Mahmoudi A, Navashenaq JG, Gheibihayat SM. Arch Microbiol 205 370 (2023)
  108. Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment. Lin M, Wang X. Pharmaceutics 16 62 (2023)
  109. Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications. Zhang X, Lin Y, Xin J, Zhang Y, Yang K, Luo Y, Wang B. Theranostics 14 220-248 (2024)
  110. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities. Zhang J, Zeng X, Guo Q, Sheng Z, Chen Y, Wan S, Zhang L, Zhang P. Exp Hematol Oncol 13 78 (2024)
  111. The Immune Response of Cancer Cells in Breast and Gynecologic Neoplasms. Rakoczy K, Kaczor J, Sołtyk A, Szymańska N, Stecko J, Drąg-Zalesińska M, Kulbacka J. Int J Mol Sci 25 6206 (2024)
  112. Tumor-associated macrophages affect the treatment of lung cancer. Yu Z, Zou J, Xu F. Heliyon 10 e29332 (2024)

Articles citing this publication (122)



Quick links